Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Triumvira

Drug class:

HER2 inhibitor, γδ TCR modulator

Related drugs:

‹

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

PF-08046052 (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

mobocertinib (12)

trastuzumab-dttb (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

BTN2A1/3A1-Fc-CD19scFv (0)

CD7-UCAR-γδT cells (0)

ET1402L1-ARTEMIS T cells (0)

Gamma delta T-cells (0)

autologous γδ T lymphocytes (0)

ALEXIS-ISO-1 (0)

NK/γδ T cell-enriched cell therapy (0)

PF-08046052 (0)

anti-CD19-CAR γδT (0)

γδT Cell infusion (0)

γδT Cell infusion agent (0)

›

HER-2 positive	Gastrointestinal Stromal Tumor	HER-2 positive	Gastrointestinal Stromal Tumor	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3
HER-2 positive	Solid Tumor	HER-2 positive	Solid Tumor	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3